Analyst Activity – Royal Bank Of Canada Raises Its Price Target On Sarepta Therapeutics (NASDAQ:SRPT) to $64.00

Analyst Ratings For Sarepta Therapeutics (NASDAQ:SRPT)

Story continues below

Today, Royal Bank Of Canada raised its price target on Sarepta Therapeutics (NASDAQ:SRPT) to $64.00 per share.

There are 3 hold ratings, 16 buy ratings, 1 strong buy rating on the stock.

The current consensus rating on Sarepta Therapeutics (NASDAQ:SRPT) is Buy (Score: 2.90) with a consensus target price of $61.90 per share, a potential 81.63% upside.

Some recent analyst ratings include

  • 7/20/2017-Cowen and Company Reiterated Rating of Outperform.
  • 7/20/2017-SunTrust Banks, Inc. Reiterated Rating of Buy.
  • 7/20/2017-Piper Jaffray Companies Reiterated Rating of Overweight.
  • 7/18/2017-Leerink Swann Reiterated Rating of Buy.
  • 7/12/2017-Robert W. Baird Reiterated Rating of Outperform.

Recent Insider Trading Activity For Sarepta Therapeutics (NASDAQ:SRPT)
Sarepta Therapeutics (NASDAQ:SRPT) has insider ownership of 9.60% and institutional ownership of 73.13%.

  • On 10/17/2016 Sandesh Mahatme, Insider, sold 30,000 with an average share price of $50.08 per share and the total transaction amounting to $1,502,400.00. View SEC Filing
  • On 9/22/2016 David T Howton, SVP, sold 7,000 with an average share price of $60.00 per share and the total transaction amounting to $420,000.00. View SEC Filing
  • On 9/22/2016 Edward M Md Kaye, CEO, sold 40,179 with an average share price of $60.00 per share and the total transaction amounting to $2,410,740.00. View SEC Filing
  • On 9/19/2016 David T Howton, SVP, sold 9,304 with an average share price of $50.00 per share and the total transaction amounting to $465,200.00. View SEC Filing
  • On 9/19/2016 Edward M Md Kaye, CEO, sold 24,352 with an average share price of $50.00 per share and the total transaction amounting to $1,217,600.00. View SEC Filing
  • On 9/19/2016 Jayant Aphale, VP, sold 35,000 with an average share price of $50.00 per share and the total transaction amounting to $1,750,000.00. View SEC Filing
  • On 9/14/2016 Edward M Md Kaye, CEO, sold 24,557 with an average share price of $30.00 per share and the total transaction amounting to $736,710.00. View SEC Filing

Recent Trading Activity for Sarepta Therapeutics (NASDAQ:SRPT)
Shares of Sarepta Therapeutics closed the previous trading session at 34.08 up +0.19 0.56% with 4,122,871 shares trading hands.

An ad to help with our costs